Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sar442085
- Development stage
- Phase 1
- Lead developer
- Sanofi
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SAR442085 is a next-generation Fc-engineered monoclonal antibody that targets the cell surface glycoprotein CD38. It was developed as an antineoplastic agent for the treatment of multiple myeloma. The drug exhibits enhanced affinity for activating Fcγ receptors (FcγRIIa and FcγRIIIa), resulting in improved natural killer (NK) cell-dependent antibody-dependent cellular cytotoxicity (ADCC) compared to earlier anti-CD38 antibodies such as daratumumab and isatuximab. Preclinical studies demonstrated superior in vitro and in vivo antimyeloma efficacy, but clinical development was discontinued during phase I trials due to strategic portfolio decisions unrelated to safety[1][2][3][4].
- Other names
- anti-CD38 monoclonal antibody SAR442085anti-CD-38 monoclonal antibody SAR442085anti-CD 38 monoclonal antibody SAR442085
02
Targets
FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)CD38 (Cluster of Differentiation 38)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on sar442085.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sar442085.